After 12 weeks of treatment, patients in the placebo group began treatment with blinded Enbrel (25 mg twice a week); patients in the active treatment groups continued to week 24 on the dose to which they were originally randomised.
Pärast 12- nädalast ravi jätkati platseebogrupil pimeda Enbreliga (25 mg kaks korda nädalas); patsiendid, kes olid aktiivravi gruppides, jätkasid kuni 24 nädalani annusega, millele nad esialgselt olid randomiseeritud.